The Antidote: Inside the World of New Pharma (74 page)

(
pp. 371
–72) Interview with Keith Johnson. Katie Thomas, and Michael S. Schmidt, “Glaxo Agrees to Pay $3 Billion in Fraud Settlement,”
New York Times
, July 2, 2012.

(
pp. 372
–76) Interviews with Josh Boger and Bo Cumbo. John Carroll, “Vertex Surges as Rival Hep C Contender Plays Catch-Up in Clinic,”
FierceBiotech
, July 31, 2012; Adam Feuerstein, “Bristol’s Hep C Drug Blow Up May Benefit Gilead, Idenix, Vertex Pharma,” TheStreet, August 2, 2012; “Idenix Shares Plunge on Hepatitis C Treatment Fears,” Bloomberg, August 16, 2012; “CDC Recommends One-Time Test for Hepatitis C for All Baby Boomers to Check for Infection,” Associated Press, August 16, 2012; Robert Weisman, “Hepatitis C Testing May Lift Vertex’s Market,”
Boston Globe
, August 18, 2012; Adam Feuerstein, “Vertex Advances One of Two Hep C Drugs,” TheStreet, September 25, 2012; Meg Tirrell, “Vertex Joins Glaxo, J&J in Testing Hepatitis C Combos,”
BloombergBusinessweek
, November 1, 2012; Ryan McBride, “Hep C Pill Race Report 2012,”
FierceBiotech
, November 14, 2012.

(
pp. 376
–79) Interview with Bo Cumbo. Susan Fernando, “Vertex’ Kalydeco Faces UK Price Pushback Though Solid Cystic Fibrosis Data Warrants Funding Settlement,”
Financial Times
, November 29, 2012; Martin Barrow, “Cystic Fibrosis Drug Kalydeco Gets NHS Funding Go-Ahead,”
London Times
, December 20, 2012; Ben Hirschler, “Analysis: Entering the Age of the $1 Million Medicine,”
Chicago Tribune
, January 3, 3013; Matthew Herper, “Inside the Pricing of a $300,000-a-Year Drug,”
Forbes
, January 3, 2013; Ben Hirschler, “Cashing in on Rare Diseases,”
Times Colonist
, January 6, 2012.

(
pp. 379
–81) Interviews with Bo Cumbo, Mark Murcko, and Peter Kolchinsky. Robert Weisman, “Surge in Federal Approvals Buoys Drug Makers,”
Boston Globe
, January 8, 2012; Meg Tirrell, “Vertex Refocuses Drug Development to Specialty Diseases,” Bloomberg, January 9, 2013; Julie M. Donnelly, “Vertex Hepatitis C Drug Revenues Plummet,”
Boston Business Journal
, January 29, 2012; Luke Timmerman, “If You’ve Got a Real Breakthrough, the FDA Wants to Talk,” Xconomy, January 14, 2012.

(
pp. 381
–83) Interview with Keith Johnson. John Carroll, “Vertex Plots a Race Through Phase III for ‘Breakthrough’ Combo CF Therapy,”
FierceBiotech
, February 26, 2013.

(
pp. 385
–89) Interviews with Josh Boger, Ken Boger, and Bink Garrison. Boger’s 2039 Annual Report, courtesy of the author.